Should Pfizer Investors Be Worried About Moderna's Lawsuits?

34
7
Favorite

Should Pfizer Investors Be Worried About Moderna's Lawsuits?

Motley Fool2022-08-31

A once-friendly rivalry isn't so friendly anymore. Moderna announced last Friday that it filed patent-infringement lawsuits against Pfizer and BioNTech in the U.S. and Germany.A portion of the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（7）

Kucing
·2022-08-31
Yes
Reply
Like
Report
Newbull
·2022-08-31
not an easy case for modena.
Reply
1
Report
blessed_1
·2022-08-31
‌[笑哭] ‌
Reply
Like
Report
BhaskarB
·2022-08-31
Ok
Reply
1
Report
BhaskarB
·2022-08-31
Nope
Reply
2
Report
Ahleepapa
·2022-08-31
short
Reply
1
Report
watever
·2022-08-31
K
Reply
2
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2263747723?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-08-31 19:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2263747723","market":"us","top_or_hot":-1,"title":"Should Pfizer Investors Be Worried About Moderna's Lawsuits?","media":"Motley Fool","content":"<div>\n<p>A once-friendly rivalry isn't so friendly anymore. Moderna  announced last Friday that it filed patent-infringement lawsuits against Pfizer and BioNTech  in the U.S. and Germany.A portion of the ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/08/31/should-pfizer-investors-be-worried-about-modernas/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should Pfizer Investors Be Worried About Moderna's Lawsuits?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould Pfizer Investors Be Worried About Moderna's Lawsuits?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-08-31 19:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/08/31/should-pfizer-investors-be-worried-about-modernas/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A once-friendly rivalry isn't so friendly anymore. Moderna  announced last Friday that it filed patent-infringement lawsuits against Pfizer and BioNTech  in the U.S. and Germany.A portion of the ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/08/31/should-pfizer-investors-be-worried-about-modernas/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PFE","symbol_name":"辉瑞","start_time":0,"source_url":"https://www.fool.com/investing/2022/08/31/should-pfizer-investors-be-worried-about-modernas/","article_id":"2263747723","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2263747723","pubTimestamp":1661946110,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"Pfizer and BioNTech plan to aggressively defend against Moderna's claims of patent infringement.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"PFE":"辉瑞","MRNA":"Moderna, Inc."},"translate_title":"辉瑞的投资者应该担心莫德纳的诉讼吗？","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":1,"MRNA":0.9},"content_text":"A once-friendly rivalry isn't so friendly anymore. Moderna  announced last Friday that it filed patent-infringement lawsuits against Pfizer and BioNTech  in the U.S. and Germany.A portion of the billions of dollars made by Pfizer and BioNTech on sales of COVID-19 vaccine Comirnaty are at stake. Should Pfizer investors be worried about Moderna's lawsuits?Moderna's complaintModerna filed several patents between 2010 and 2016 related to its messenger RNA (mRNA) technology. This technology was foundational for the company's development of COVID-19 vaccine Spikevax. Moderna's mRNA vaccine won U.S. Emergency Use Authorization in December 2020 and secured full Food and Drug Administration (FDA) approval in January 2022.The crux of Moderna's lawsuits is an allegation that Pfizer and BioNTech's COVID-19 vaccine Comirnaty infringes on those patents. Moderna Chief Legal Officer Shannon Thyme Klinger stated in the company's press release last week: \"We believe that Pfizer and BioNTech unlawfully copied Moderna's inventions, and they have continued to use them without permission.\"Moderna maintains that Pfizer and BioNTech advanced four COVID-19 vaccine candidates into clinical testing but ultimately picked one with the exact same mRNA chemical modification as Spikevax. It also alleges that Pfizer and BioNTech copied an approach developed by Moderna for encoding the full-length spike protein found on the surface of the novel coronavirus in a lipid nanoparticle formulation.In October 2020, Moderna pledged that it wouldn't seek to enforce its COVID-19 patents during the pandemic. However, the company updated that pledge in March 2022 with COVID-19 vaccines readily available throughout much of the world. Moderna's revised commitment was to never enforce its patents for COVID-19 vaccines used in low- and middle-income countries. But the company didn't extend that promise to major developed markets.Potential impactWhat's the potential impact on Pfizer? Most importantly, Moderna isn't trying to remove Comirnaty from the market. Nor is it trying to prevent any future sales of the vaccine. Neither is Moderna seeking damages related to Pfizer's sales in any of the 92 countries covered in the GAVI COVAX Advance Market Commitment (known as AMC 92 countries).Pfizer and BioNTech could, though, be liable for patent infringement (if proven) related to any sales of Comirnaty outside of the AMC 92 countries from March 8, 2022 and afterward. This date is based on when Moderna updated its pledge related to enforcement of its COVID-19 patents.In the second quarter of 2022, Pfizer recorded $8.8 billion in sales of Comirnaty. Based on the big drugmaker's guidance, another $10 billion will be made in the second half of this year. We don't know exactly how much of Comirnaty's sales were from March 8 through the end of Q1, but it's likely at least in the ballpark of $3.4 billion. Adding all of this up, Pfizer will probably record more than $22 billion in sales of Comirnaty this year to which Moderna is seeking damages.Moderna didn't indicate the licensing terms that it thinks are acceptable. Should Moderna win in court, a 20% royalty (which isn't unusual) would require Pfizer and BioNTech to pay around $4.4 billion to Moderna plus any punitive damages assessed along with royalties on future sales of Comirnaty. Of course, Pfizer and BioNTech would share the financial burden.No worries?It's pretty clear that Pfizer investors aren't all that worried about the Moderna lawsuits. The big drugmaker's share price is down only slightly since the litigation was announced. As for BioNTech, the vaccine stock is actually up a little.Pfizer said in a written statement to CNN that it hasn't fully reviewed Moderna's complaint but was \"surprised by the litigation\" and would \"vigorously defend against the allegations of the lawsuit.\" Similarly, BioNTech said in a public statement that its \"work is original, and will vigorously defend against all allegations of patent infringement.\" BioNTech noted that these kinds of patent lawsuits are \"an unfortunate but rather regular occurrence.\"The courts will have to determine which side is right. However, Pfizer is making so much money from Comirnaty that it shouldn't feel too much pain even if Moderna wins.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9930205899,"gmtCreate":1661959292413,"gmtModify":1676536612518,"author":{"id":"3584520268259172","authorId":"3584520268259172","name":"Kucing","avatar":"https://static.tigerbbs.com/3c4942db49a9ed9bfaecacc7837dec2f","vip":1,"crmLevel":6,"crmLevelSwitch":1,"authorIdStr":"3584520268259172","idStr":"3584520268259172"},"htmlText":"Yes&nbsp;","listText":"Yes&nbsp;","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9930205899","repostId":2263747723,"repostType":4,"repost":{"id":"2263747723","pubTimestamp":1661946110,"share":"https://ttm.financial/m/news/2263747723?lang=&edition=fundamental","pubTime":"2022-08-31 19:41","market":"us","language":"en","title":"Should Pfizer Investors Be Worried About Moderna's Lawsuits?","url":"https://stock-news.laohu8.com/highlight/detail?id=2263747723","media":"Motley Fool","summary":"Pfizer and BioNTech plan to aggressively defend against Moderna's claims of patent infringement.","content":"<html><head></head><body><p>A once-friendly rivalry isn&#39;t so friendly anymore. <a href=\"https://laohu8.com/S/MRNA\">Moderna </a> announced last Friday that it filed patent-infringement lawsuits against <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech </a> in the U.S. and Germany.</p><p>A portion of the billions of dollars made by Pfizer and BioNTech on sales of COVID-19 vaccine Comirnaty are at stake. Should Pfizer investors be worried about Moderna&#39;s lawsuits?</p><h2>Moderna&#39;s complaint</h2><p>Moderna filed several patents between 2010 and 2016 related to its messenger RNA (mRNA) technology. This technology was foundational for the company&#39;s development of COVID-19 vaccine Spikevax. Moderna&#39;s mRNA vaccine won U.S. Emergency Use Authorization in December 2020 and secured full Food and Drug Administration (FDA) approval in January 2022.</p><p>The crux of Moderna&#39;s lawsuits is an allegation that Pfizer and BioNTech&#39;s COVID-19 vaccine Comirnaty infringes on those patents. Moderna Chief Legal Officer Shannon Thyme Klinger stated in the company&#39;s press release last week: &#34;We believe that Pfizer and BioNTech unlawfully copied Moderna&#39;s inventions, and they have continued to use them without permission.&#34;</p><p>Moderna maintains that Pfizer and BioNTech advanced four COVID-19 vaccine candidates into clinical testing but ultimately picked one with the exact same mRNA chemical modification as Spikevax. It also alleges that Pfizer and BioNTech copied an approach developed by Moderna for encoding the full-length spike protein found on the surface of the novel coronavirus in a lipid nanoparticle formulation.</p><p>In October 2020, Moderna pledged that it wouldn&#39;t seek to enforce its COVID-19 patents during the pandemic. However, the company updated that pledge in March 2022 with COVID-19 vaccines readily available throughout much of the world. Moderna&#39;s revised commitment was to never enforce its patents for COVID-19 vaccines used in low- and middle-income countries. But the company didn&#39;t extend that promise to major developed markets.</p><h2>Potential impact</h2><p>What&#39;s the potential impact on Pfizer? Most importantly, Moderna isn&#39;t trying to remove Comirnaty from the market. Nor is it trying to prevent any future sales of the vaccine. Neither is Moderna seeking damages related to Pfizer&#39;s sales in any of the 92 countries covered in the GAVI COVAX Advance Market Commitment (known as AMC 92 countries).</p><p>Pfizer and BioNTech could, though, be liable for patent infringement (if proven) related to any sales of Comirnaty outside of the AMC 92 countries from March 8, 2022 and afterward. This date is based on when Moderna updated its pledge related to enforcement of its COVID-19 patents.</p><p>In the second quarter of 2022, Pfizer recorded $8.8 billion in sales of Comirnaty. Based on the big drugmaker&#39;s guidance, another $10 billion will be made in the second half of this year. We don&#39;t know exactly how much of Comirnaty&#39;s sales were from March 8 through the end of Q1, but it&#39;s likely at least in the ballpark of $3.4 billion. Adding all of this up, Pfizer will probably record more than $22 billion in sales of Comirnaty this year to which Moderna is seeking damages.</p><p>Moderna didn&#39;t indicate the licensing terms that it thinks are acceptable. Should Moderna win in court, a 20% royalty (which isn&#39;t unusual) would require Pfizer and BioNTech to pay around $4.4 billion to Moderna plus any punitive damages assessed along with royalties on future sales of Comirnaty. Of course, Pfizer and BioNTech would share the financial burden.</p><h2>No worries?</h2><p>It&#39;s pretty clear that Pfizer investors aren&#39;t all that worried about the Moderna lawsuits. The big drugmaker&#39;s share price is down only slightly since the litigation was announced. As for BioNTech, the vaccine stock is actually up a little.</p><p>Pfizer said in a written statement to CNN that it hasn&#39;t fully reviewed Moderna&#39;s complaint but was &#34;surprised by the litigation&#34; and would &#34;vigorously defend against the allegations of the lawsuit.&#34; Similarly, BioNTech said in a public statement that its &#34;work is original, and will vigorously defend against all allegations of patent infringement.&#34; BioNTech noted that these kinds of patent lawsuits are &#34;an unfortunate but rather regular occurrence.&#34;</p><p>The courts will have to determine which side is right. However, Pfizer is making so much money from Comirnaty that it shouldn&#39;t feel too much pain even if Moderna wins.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should Pfizer Investors Be Worried About Moderna's Lawsuits?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould Pfizer Investors Be Worried About Moderna's Lawsuits?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-08-31 19:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/08/31/should-pfizer-investors-be-worried-about-modernas/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A once-friendly rivalry isn't so friendly anymore. Moderna  announced last Friday that it filed patent-infringement lawsuits against Pfizer and BioNTech  in the U.S. and Germany.A portion of the ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/08/31/should-pfizer-investors-be-worried-about-modernas/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2022/08/31/should-pfizer-investors-be-worried-about-modernas/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2263747723","content_text":"A once-friendly rivalry isn't so friendly anymore. Moderna  announced last Friday that it filed patent-infringement lawsuits against Pfizer and BioNTech  in the U.S. and Germany.A portion of the billions of dollars made by Pfizer and BioNTech on sales of COVID-19 vaccine Comirnaty are at stake. Should Pfizer investors be worried about Moderna's lawsuits?Moderna's complaintModerna filed several patents between 2010 and 2016 related to its messenger RNA (mRNA) technology. This technology was foundational for the company's development of COVID-19 vaccine Spikevax. Moderna's mRNA vaccine won U.S. Emergency Use Authorization in December 2020 and secured full Food and Drug Administration (FDA) approval in January 2022.The crux of Moderna's lawsuits is an allegation that Pfizer and BioNTech's COVID-19 vaccine Comirnaty infringes on those patents. Moderna Chief Legal Officer Shannon Thyme Klinger stated in the company's press release last week: \"We believe that Pfizer and BioNTech unlawfully copied Moderna's inventions, and they have continued to use them without permission.\"Moderna maintains that Pfizer and BioNTech advanced four COVID-19 vaccine candidates into clinical testing but ultimately picked one with the exact same mRNA chemical modification as Spikevax. It also alleges that Pfizer and BioNTech copied an approach developed by Moderna for encoding the full-length spike protein found on the surface of the novel coronavirus in a lipid nanoparticle formulation.In October 2020, Moderna pledged that it wouldn't seek to enforce its COVID-19 patents during the pandemic. However, the company updated that pledge in March 2022 with COVID-19 vaccines readily available throughout much of the world. Moderna's revised commitment was to never enforce its patents for COVID-19 vaccines used in low- and middle-income countries. But the company didn't extend that promise to major developed markets.Potential impactWhat's the potential impact on Pfizer? Most importantly, Moderna isn't trying to remove Comirnaty from the market. Nor is it trying to prevent any future sales of the vaccine. Neither is Moderna seeking damages related to Pfizer's sales in any of the 92 countries covered in the GAVI COVAX Advance Market Commitment (known as AMC 92 countries).Pfizer and BioNTech could, though, be liable for patent infringement (if proven) related to any sales of Comirnaty outside of the AMC 92 countries from March 8, 2022 and afterward. This date is based on when Moderna updated its pledge related to enforcement of its COVID-19 patents.In the second quarter of 2022, Pfizer recorded $8.8 billion in sales of Comirnaty. Based on the big drugmaker's guidance, another $10 billion will be made in the second half of this year. We don't know exactly how much of Comirnaty's sales were from March 8 through the end of Q1, but it's likely at least in the ballpark of $3.4 billion. Adding all of this up, Pfizer will probably record more than $22 billion in sales of Comirnaty this year to which Moderna is seeking damages.Moderna didn't indicate the licensing terms that it thinks are acceptable. Should Moderna win in court, a 20% royalty (which isn't unusual) would require Pfizer and BioNTech to pay around $4.4 billion to Moderna plus any punitive damages assessed along with royalties on future sales of Comirnaty. Of course, Pfizer and BioNTech would share the financial burden.No worries?It's pretty clear that Pfizer investors aren't all that worried about the Moderna lawsuits. The big drugmaker's share price is down only slightly since the litigation was announced. As for BioNTech, the vaccine stock is actually up a little.Pfizer said in a written statement to CNN that it hasn't fully reviewed Moderna's complaint but was \"surprised by the litigation\" and would \"vigorously defend against the allegations of the lawsuit.\" Similarly, BioNTech said in a public statement that its \"work is original, and will vigorously defend against all allegations of patent infringement.\" BioNTech noted that these kinds of patent lawsuits are \"an unfortunate but rather regular occurrence.\"The courts will have to determine which side is right. However, Pfizer is making so much money from Comirnaty that it shouldn't feel too much pain even if Moderna wins.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9930629041,"gmtCreate":1661953344585,"gmtModify":1676536610711,"author":{"id":"4101367049328400","authorId":"4101367049328400","name":"Newbull","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"authorIdStr":"4101367049328400","idStr":"4101367049328400"},"htmlText":"not an easy case for modena.","listText":"not an easy case for modena.","text":"not an easy case for modena.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9930629041","repostId":2263747723,"repostType":4,"repost":{"id":"2263747723","pubTimestamp":1661946110,"share":"https://ttm.financial/m/news/2263747723?lang=&edition=fundamental","pubTime":"2022-08-31 19:41","market":"us","language":"en","title":"Should Pfizer Investors Be Worried About Moderna's Lawsuits?","url":"https://stock-news.laohu8.com/highlight/detail?id=2263747723","media":"Motley Fool","summary":"Pfizer and BioNTech plan to aggressively defend against Moderna's claims of patent infringement.","content":"<html><head></head><body><p>A once-friendly rivalry isn&#39;t so friendly anymore. <a href=\"https://laohu8.com/S/MRNA\">Moderna </a> announced last Friday that it filed patent-infringement lawsuits against <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech </a> in the U.S. and Germany.</p><p>A portion of the billions of dollars made by Pfizer and BioNTech on sales of COVID-19 vaccine Comirnaty are at stake. Should Pfizer investors be worried about Moderna&#39;s lawsuits?</p><h2>Moderna&#39;s complaint</h2><p>Moderna filed several patents between 2010 and 2016 related to its messenger RNA (mRNA) technology. This technology was foundational for the company&#39;s development of COVID-19 vaccine Spikevax. Moderna&#39;s mRNA vaccine won U.S. Emergency Use Authorization in December 2020 and secured full Food and Drug Administration (FDA) approval in January 2022.</p><p>The crux of Moderna&#39;s lawsuits is an allegation that Pfizer and BioNTech&#39;s COVID-19 vaccine Comirnaty infringes on those patents. Moderna Chief Legal Officer Shannon Thyme Klinger stated in the company&#39;s press release last week: &#34;We believe that Pfizer and BioNTech unlawfully copied Moderna&#39;s inventions, and they have continued to use them without permission.&#34;</p><p>Moderna maintains that Pfizer and BioNTech advanced four COVID-19 vaccine candidates into clinical testing but ultimately picked one with the exact same mRNA chemical modification as Spikevax. It also alleges that Pfizer and BioNTech copied an approach developed by Moderna for encoding the full-length spike protein found on the surface of the novel coronavirus in a lipid nanoparticle formulation.</p><p>In October 2020, Moderna pledged that it wouldn&#39;t seek to enforce its COVID-19 patents during the pandemic. However, the company updated that pledge in March 2022 with COVID-19 vaccines readily available throughout much of the world. Moderna&#39;s revised commitment was to never enforce its patents for COVID-19 vaccines used in low- and middle-income countries. But the company didn&#39;t extend that promise to major developed markets.</p><h2>Potential impact</h2><p>What&#39;s the potential impact on Pfizer? Most importantly, Moderna isn&#39;t trying to remove Comirnaty from the market. Nor is it trying to prevent any future sales of the vaccine. Neither is Moderna seeking damages related to Pfizer&#39;s sales in any of the 92 countries covered in the GAVI COVAX Advance Market Commitment (known as AMC 92 countries).</p><p>Pfizer and BioNTech could, though, be liable for patent infringement (if proven) related to any sales of Comirnaty outside of the AMC 92 countries from March 8, 2022 and afterward. This date is based on when Moderna updated its pledge related to enforcement of its COVID-19 patents.</p><p>In the second quarter of 2022, Pfizer recorded $8.8 billion in sales of Comirnaty. Based on the big drugmaker&#39;s guidance, another $10 billion will be made in the second half of this year. We don&#39;t know exactly how much of Comirnaty&#39;s sales were from March 8 through the end of Q1, but it&#39;s likely at least in the ballpark of $3.4 billion. Adding all of this up, Pfizer will probably record more than $22 billion in sales of Comirnaty this year to which Moderna is seeking damages.</p><p>Moderna didn&#39;t indicate the licensing terms that it thinks are acceptable. Should Moderna win in court, a 20% royalty (which isn&#39;t unusual) would require Pfizer and BioNTech to pay around $4.4 billion to Moderna plus any punitive damages assessed along with royalties on future sales of Comirnaty. Of course, Pfizer and BioNTech would share the financial burden.</p><h2>No worries?</h2><p>It&#39;s pretty clear that Pfizer investors aren&#39;t all that worried about the Moderna lawsuits. The big drugmaker&#39;s share price is down only slightly since the litigation was announced. As for BioNTech, the vaccine stock is actually up a little.</p><p>Pfizer said in a written statement to CNN that it hasn&#39;t fully reviewed Moderna&#39;s complaint but was &#34;surprised by the litigation&#34; and would &#34;vigorously defend against the allegations of the lawsuit.&#34; Similarly, BioNTech said in a public statement that its &#34;work is original, and will vigorously defend against all allegations of patent infringement.&#34; BioNTech noted that these kinds of patent lawsuits are &#34;an unfortunate but rather regular occurrence.&#34;</p><p>The courts will have to determine which side is right. However, Pfizer is making so much money from Comirnaty that it shouldn&#39;t feel too much pain even if Moderna wins.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should Pfizer Investors Be Worried About Moderna's Lawsuits?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould Pfizer Investors Be Worried About Moderna's Lawsuits?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-08-31 19:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/08/31/should-pfizer-investors-be-worried-about-modernas/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A once-friendly rivalry isn't so friendly anymore. Moderna  announced last Friday that it filed patent-infringement lawsuits against Pfizer and BioNTech  in the U.S. and Germany.A portion of the ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/08/31/should-pfizer-investors-be-worried-about-modernas/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2022/08/31/should-pfizer-investors-be-worried-about-modernas/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2263747723","content_text":"A once-friendly rivalry isn't so friendly anymore. Moderna  announced last Friday that it filed patent-infringement lawsuits against Pfizer and BioNTech  in the U.S. and Germany.A portion of the billions of dollars made by Pfizer and BioNTech on sales of COVID-19 vaccine Comirnaty are at stake. Should Pfizer investors be worried about Moderna's lawsuits?Moderna's complaintModerna filed several patents between 2010 and 2016 related to its messenger RNA (mRNA) technology. This technology was foundational for the company's development of COVID-19 vaccine Spikevax. Moderna's mRNA vaccine won U.S. Emergency Use Authorization in December 2020 and secured full Food and Drug Administration (FDA) approval in January 2022.The crux of Moderna's lawsuits is an allegation that Pfizer and BioNTech's COVID-19 vaccine Comirnaty infringes on those patents. Moderna Chief Legal Officer Shannon Thyme Klinger stated in the company's press release last week: \"We believe that Pfizer and BioNTech unlawfully copied Moderna's inventions, and they have continued to use them without permission.\"Moderna maintains that Pfizer and BioNTech advanced four COVID-19 vaccine candidates into clinical testing but ultimately picked one with the exact same mRNA chemical modification as Spikevax. It also alleges that Pfizer and BioNTech copied an approach developed by Moderna for encoding the full-length spike protein found on the surface of the novel coronavirus in a lipid nanoparticle formulation.In October 2020, Moderna pledged that it wouldn't seek to enforce its COVID-19 patents during the pandemic. However, the company updated that pledge in March 2022 with COVID-19 vaccines readily available throughout much of the world. Moderna's revised commitment was to never enforce its patents for COVID-19 vaccines used in low- and middle-income countries. But the company didn't extend that promise to major developed markets.Potential impactWhat's the potential impact on Pfizer? Most importantly, Moderna isn't trying to remove Comirnaty from the market. Nor is it trying to prevent any future sales of the vaccine. Neither is Moderna seeking damages related to Pfizer's sales in any of the 92 countries covered in the GAVI COVAX Advance Market Commitment (known as AMC 92 countries).Pfizer and BioNTech could, though, be liable for patent infringement (if proven) related to any sales of Comirnaty outside of the AMC 92 countries from March 8, 2022 and afterward. This date is based on when Moderna updated its pledge related to enforcement of its COVID-19 patents.In the second quarter of 2022, Pfizer recorded $8.8 billion in sales of Comirnaty. Based on the big drugmaker's guidance, another $10 billion will be made in the second half of this year. We don't know exactly how much of Comirnaty's sales were from March 8 through the end of Q1, but it's likely at least in the ballpark of $3.4 billion. Adding all of this up, Pfizer will probably record more than $22 billion in sales of Comirnaty this year to which Moderna is seeking damages.Moderna didn't indicate the licensing terms that it thinks are acceptable. Should Moderna win in court, a 20% royalty (which isn't unusual) would require Pfizer and BioNTech to pay around $4.4 billion to Moderna plus any punitive damages assessed along with royalties on future sales of Comirnaty. Of course, Pfizer and BioNTech would share the financial burden.No worries?It's pretty clear that Pfizer investors aren't all that worried about the Moderna lawsuits. The big drugmaker's share price is down only slightly since the litigation was announced. As for BioNTech, the vaccine stock is actually up a little.Pfizer said in a written statement to CNN that it hasn't fully reviewed Moderna's complaint but was \"surprised by the litigation\" and would \"vigorously defend against the allegations of the lawsuit.\" Similarly, BioNTech said in a public statement that its \"work is original, and will vigorously defend against all allegations of patent infringement.\" BioNTech noted that these kinds of patent lawsuits are \"an unfortunate but rather regular occurrence.\"The courts will have to determine which side is right. However, Pfizer is making so much money from Comirnaty that it shouldn't feel too much pain even if Moderna wins.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9930661148,"gmtCreate":1661952325986,"gmtModify":1676536610480,"author":{"id":"4112410321254552","authorId":"4112410321254552","name":"blessed_1","avatar":"https://community-static.tradeup.com/news/71622697830d9517eb67a61917d8a95f","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":4,"crmLevelSwitch":1,"authorIdStr":"4112410321254552","idStr":"4112410321254552"},"htmlText":"‌<a href=\"\">[笑哭]&nbsp;</a>‌","listText":"‌<a href=\"\">[笑哭]&nbsp;</a>‌","text":"‌[笑哭] ‌","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9930661148","repostId":2263747723,"repostType":4,"repost":{"id":"2263747723","pubTimestamp":1661946110,"share":"https://ttm.financial/m/news/2263747723?lang=&edition=fundamental","pubTime":"2022-08-31 19:41","market":"us","language":"en","title":"Should Pfizer Investors Be Worried About Moderna's Lawsuits?","url":"https://stock-news.laohu8.com/highlight/detail?id=2263747723","media":"Motley Fool","summary":"Pfizer and BioNTech plan to aggressively defend against Moderna's claims of patent infringement.","content":"<html><head></head><body><p>A once-friendly rivalry isn&#39;t so friendly anymore. <a href=\"https://laohu8.com/S/MRNA\">Moderna </a> announced last Friday that it filed patent-infringement lawsuits against <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech </a> in the U.S. and Germany.</p><p>A portion of the billions of dollars made by Pfizer and BioNTech on sales of COVID-19 vaccine Comirnaty are at stake. Should Pfizer investors be worried about Moderna&#39;s lawsuits?</p><h2>Moderna&#39;s complaint</h2><p>Moderna filed several patents between 2010 and 2016 related to its messenger RNA (mRNA) technology. This technology was foundational for the company&#39;s development of COVID-19 vaccine Spikevax. Moderna&#39;s mRNA vaccine won U.S. Emergency Use Authorization in December 2020 and secured full Food and Drug Administration (FDA) approval in January 2022.</p><p>The crux of Moderna&#39;s lawsuits is an allegation that Pfizer and BioNTech&#39;s COVID-19 vaccine Comirnaty infringes on those patents. Moderna Chief Legal Officer Shannon Thyme Klinger stated in the company&#39;s press release last week: &#34;We believe that Pfizer and BioNTech unlawfully copied Moderna&#39;s inventions, and they have continued to use them without permission.&#34;</p><p>Moderna maintains that Pfizer and BioNTech advanced four COVID-19 vaccine candidates into clinical testing but ultimately picked one with the exact same mRNA chemical modification as Spikevax. It also alleges that Pfizer and BioNTech copied an approach developed by Moderna for encoding the full-length spike protein found on the surface of the novel coronavirus in a lipid nanoparticle formulation.</p><p>In October 2020, Moderna pledged that it wouldn&#39;t seek to enforce its COVID-19 patents during the pandemic. However, the company updated that pledge in March 2022 with COVID-19 vaccines readily available throughout much of the world. Moderna&#39;s revised commitment was to never enforce its patents for COVID-19 vaccines used in low- and middle-income countries. But the company didn&#39;t extend that promise to major developed markets.</p><h2>Potential impact</h2><p>What&#39;s the potential impact on Pfizer? Most importantly, Moderna isn&#39;t trying to remove Comirnaty from the market. Nor is it trying to prevent any future sales of the vaccine. Neither is Moderna seeking damages related to Pfizer&#39;s sales in any of the 92 countries covered in the GAVI COVAX Advance Market Commitment (known as AMC 92 countries).</p><p>Pfizer and BioNTech could, though, be liable for patent infringement (if proven) related to any sales of Comirnaty outside of the AMC 92 countries from March 8, 2022 and afterward. This date is based on when Moderna updated its pledge related to enforcement of its COVID-19 patents.</p><p>In the second quarter of 2022, Pfizer recorded $8.8 billion in sales of Comirnaty. Based on the big drugmaker&#39;s guidance, another $10 billion will be made in the second half of this year. We don&#39;t know exactly how much of Comirnaty&#39;s sales were from March 8 through the end of Q1, but it&#39;s likely at least in the ballpark of $3.4 billion. Adding all of this up, Pfizer will probably record more than $22 billion in sales of Comirnaty this year to which Moderna is seeking damages.</p><p>Moderna didn&#39;t indicate the licensing terms that it thinks are acceptable. Should Moderna win in court, a 20% royalty (which isn&#39;t unusual) would require Pfizer and BioNTech to pay around $4.4 billion to Moderna plus any punitive damages assessed along with royalties on future sales of Comirnaty. Of course, Pfizer and BioNTech would share the financial burden.</p><h2>No worries?</h2><p>It&#39;s pretty clear that Pfizer investors aren&#39;t all that worried about the Moderna lawsuits. The big drugmaker&#39;s share price is down only slightly since the litigation was announced. As for BioNTech, the vaccine stock is actually up a little.</p><p>Pfizer said in a written statement to CNN that it hasn&#39;t fully reviewed Moderna&#39;s complaint but was &#34;surprised by the litigation&#34; and would &#34;vigorously defend against the allegations of the lawsuit.&#34; Similarly, BioNTech said in a public statement that its &#34;work is original, and will vigorously defend against all allegations of patent infringement.&#34; BioNTech noted that these kinds of patent lawsuits are &#34;an unfortunate but rather regular occurrence.&#34;</p><p>The courts will have to determine which side is right. However, Pfizer is making so much money from Comirnaty that it shouldn&#39;t feel too much pain even if Moderna wins.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should Pfizer Investors Be Worried About Moderna's Lawsuits?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould Pfizer Investors Be Worried About Moderna's Lawsuits?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-08-31 19:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/08/31/should-pfizer-investors-be-worried-about-modernas/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A once-friendly rivalry isn't so friendly anymore. Moderna  announced last Friday that it filed patent-infringement lawsuits against Pfizer and BioNTech  in the U.S. and Germany.A portion of the ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/08/31/should-pfizer-investors-be-worried-about-modernas/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2022/08/31/should-pfizer-investors-be-worried-about-modernas/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2263747723","content_text":"A once-friendly rivalry isn't so friendly anymore. Moderna  announced last Friday that it filed patent-infringement lawsuits against Pfizer and BioNTech  in the U.S. and Germany.A portion of the billions of dollars made by Pfizer and BioNTech on sales of COVID-19 vaccine Comirnaty are at stake. Should Pfizer investors be worried about Moderna's lawsuits?Moderna's complaintModerna filed several patents between 2010 and 2016 related to its messenger RNA (mRNA) technology. This technology was foundational for the company's development of COVID-19 vaccine Spikevax. Moderna's mRNA vaccine won U.S. Emergency Use Authorization in December 2020 and secured full Food and Drug Administration (FDA) approval in January 2022.The crux of Moderna's lawsuits is an allegation that Pfizer and BioNTech's COVID-19 vaccine Comirnaty infringes on those patents. Moderna Chief Legal Officer Shannon Thyme Klinger stated in the company's press release last week: \"We believe that Pfizer and BioNTech unlawfully copied Moderna's inventions, and they have continued to use them without permission.\"Moderna maintains that Pfizer and BioNTech advanced four COVID-19 vaccine candidates into clinical testing but ultimately picked one with the exact same mRNA chemical modification as Spikevax. It also alleges that Pfizer and BioNTech copied an approach developed by Moderna for encoding the full-length spike protein found on the surface of the novel coronavirus in a lipid nanoparticle formulation.In October 2020, Moderna pledged that it wouldn't seek to enforce its COVID-19 patents during the pandemic. However, the company updated that pledge in March 2022 with COVID-19 vaccines readily available throughout much of the world. Moderna's revised commitment was to never enforce its patents for COVID-19 vaccines used in low- and middle-income countries. But the company didn't extend that promise to major developed markets.Potential impactWhat's the potential impact on Pfizer? Most importantly, Moderna isn't trying to remove Comirnaty from the market. Nor is it trying to prevent any future sales of the vaccine. Neither is Moderna seeking damages related to Pfizer's sales in any of the 92 countries covered in the GAVI COVAX Advance Market Commitment (known as AMC 92 countries).Pfizer and BioNTech could, though, be liable for patent infringement (if proven) related to any sales of Comirnaty outside of the AMC 92 countries from March 8, 2022 and afterward. This date is based on when Moderna updated its pledge related to enforcement of its COVID-19 patents.In the second quarter of 2022, Pfizer recorded $8.8 billion in sales of Comirnaty. Based on the big drugmaker's guidance, another $10 billion will be made in the second half of this year. We don't know exactly how much of Comirnaty's sales were from March 8 through the end of Q1, but it's likely at least in the ballpark of $3.4 billion. Adding all of this up, Pfizer will probably record more than $22 billion in sales of Comirnaty this year to which Moderna is seeking damages.Moderna didn't indicate the licensing terms that it thinks are acceptable. Should Moderna win in court, a 20% royalty (which isn't unusual) would require Pfizer and BioNTech to pay around $4.4 billion to Moderna plus any punitive damages assessed along with royalties on future sales of Comirnaty. Of course, Pfizer and BioNTech would share the financial burden.No worries?It's pretty clear that Pfizer investors aren't all that worried about the Moderna lawsuits. The big drugmaker's share price is down only slightly since the litigation was announced. As for BioNTech, the vaccine stock is actually up a little.Pfizer said in a written statement to CNN that it hasn't fully reviewed Moderna's complaint but was \"surprised by the litigation\" and would \"vigorously defend against the allegations of the lawsuit.\" Similarly, BioNTech said in a public statement that its \"work is original, and will vigorously defend against all allegations of patent infringement.\" BioNTech noted that these kinds of patent lawsuits are \"an unfortunate but rather regular occurrence.\"The courts will have to determine which side is right. However, Pfizer is making so much money from Comirnaty that it shouldn't feel too much pain even if Moderna wins.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":9930684294,"gmtCreate":1661951632520,"gmtModify":1676536610281,"author":{"id":"3576055655100541","authorId":"3576055655100541","name":"BhaskarB","avatar":"https://static.tigerbbs.com/ae63d5d863287dbf3e7d25ef9ab845e0","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3576055655100541","idStr":"3576055655100541"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9930684294","repostId":2263747723,"repostType":4,"repost":{"id":"2263747723","pubTimestamp":1661946110,"share":"https://ttm.financial/m/news/2263747723?lang=&edition=fundamental","pubTime":"2022-08-31 19:41","market":"us","language":"en","title":"Should Pfizer Investors Be Worried About Moderna's Lawsuits?","url":"https://stock-news.laohu8.com/highlight/detail?id=2263747723","media":"Motley Fool","summary":"Pfizer and BioNTech plan to aggressively defend against Moderna's claims of patent infringement.","content":"<html><head></head><body><p>A once-friendly rivalry isn&#39;t so friendly anymore. <a href=\"https://laohu8.com/S/MRNA\">Moderna </a> announced last Friday that it filed patent-infringement lawsuits against <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech </a> in the U.S. and Germany.</p><p>A portion of the billions of dollars made by Pfizer and BioNTech on sales of COVID-19 vaccine Comirnaty are at stake. Should Pfizer investors be worried about Moderna&#39;s lawsuits?</p><h2>Moderna&#39;s complaint</h2><p>Moderna filed several patents between 2010 and 2016 related to its messenger RNA (mRNA) technology. This technology was foundational for the company&#39;s development of COVID-19 vaccine Spikevax. Moderna&#39;s mRNA vaccine won U.S. Emergency Use Authorization in December 2020 and secured full Food and Drug Administration (FDA) approval in January 2022.</p><p>The crux of Moderna&#39;s lawsuits is an allegation that Pfizer and BioNTech&#39;s COVID-19 vaccine Comirnaty infringes on those patents. Moderna Chief Legal Officer Shannon Thyme Klinger stated in the company&#39;s press release last week: &#34;We believe that Pfizer and BioNTech unlawfully copied Moderna&#39;s inventions, and they have continued to use them without permission.&#34;</p><p>Moderna maintains that Pfizer and BioNTech advanced four COVID-19 vaccine candidates into clinical testing but ultimately picked one with the exact same mRNA chemical modification as Spikevax. It also alleges that Pfizer and BioNTech copied an approach developed by Moderna for encoding the full-length spike protein found on the surface of the novel coronavirus in a lipid nanoparticle formulation.</p><p>In October 2020, Moderna pledged that it wouldn&#39;t seek to enforce its COVID-19 patents during the pandemic. However, the company updated that pledge in March 2022 with COVID-19 vaccines readily available throughout much of the world. Moderna&#39;s revised commitment was to never enforce its patents for COVID-19 vaccines used in low- and middle-income countries. But the company didn&#39;t extend that promise to major developed markets.</p><h2>Potential impact</h2><p>What&#39;s the potential impact on Pfizer? Most importantly, Moderna isn&#39;t trying to remove Comirnaty from the market. Nor is it trying to prevent any future sales of the vaccine. Neither is Moderna seeking damages related to Pfizer&#39;s sales in any of the 92 countries covered in the GAVI COVAX Advance Market Commitment (known as AMC 92 countries).</p><p>Pfizer and BioNTech could, though, be liable for patent infringement (if proven) related to any sales of Comirnaty outside of the AMC 92 countries from March 8, 2022 and afterward. This date is based on when Moderna updated its pledge related to enforcement of its COVID-19 patents.</p><p>In the second quarter of 2022, Pfizer recorded $8.8 billion in sales of Comirnaty. Based on the big drugmaker&#39;s guidance, another $10 billion will be made in the second half of this year. We don&#39;t know exactly how much of Comirnaty&#39;s sales were from March 8 through the end of Q1, but it&#39;s likely at least in the ballpark of $3.4 billion. Adding all of this up, Pfizer will probably record more than $22 billion in sales of Comirnaty this year to which Moderna is seeking damages.</p><p>Moderna didn&#39;t indicate the licensing terms that it thinks are acceptable. Should Moderna win in court, a 20% royalty (which isn&#39;t unusual) would require Pfizer and BioNTech to pay around $4.4 billion to Moderna plus any punitive damages assessed along with royalties on future sales of Comirnaty. Of course, Pfizer and BioNTech would share the financial burden.</p><h2>No worries?</h2><p>It&#39;s pretty clear that Pfizer investors aren&#39;t all that worried about the Moderna lawsuits. The big drugmaker&#39;s share price is down only slightly since the litigation was announced. As for BioNTech, the vaccine stock is actually up a little.</p><p>Pfizer said in a written statement to CNN that it hasn&#39;t fully reviewed Moderna&#39;s complaint but was &#34;surprised by the litigation&#34; and would &#34;vigorously defend against the allegations of the lawsuit.&#34; Similarly, BioNTech said in a public statement that its &#34;work is original, and will vigorously defend against all allegations of patent infringement.&#34; BioNTech noted that these kinds of patent lawsuits are &#34;an unfortunate but rather regular occurrence.&#34;</p><p>The courts will have to determine which side is right. However, Pfizer is making so much money from Comirnaty that it shouldn&#39;t feel too much pain even if Moderna wins.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should Pfizer Investors Be Worried About Moderna's Lawsuits?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould Pfizer Investors Be Worried About Moderna's Lawsuits?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-08-31 19:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/08/31/should-pfizer-investors-be-worried-about-modernas/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A once-friendly rivalry isn't so friendly anymore. Moderna  announced last Friday that it filed patent-infringement lawsuits against Pfizer and BioNTech  in the U.S. and Germany.A portion of the ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/08/31/should-pfizer-investors-be-worried-about-modernas/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2022/08/31/should-pfizer-investors-be-worried-about-modernas/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2263747723","content_text":"A once-friendly rivalry isn't so friendly anymore. Moderna  announced last Friday that it filed patent-infringement lawsuits against Pfizer and BioNTech  in the U.S. and Germany.A portion of the billions of dollars made by Pfizer and BioNTech on sales of COVID-19 vaccine Comirnaty are at stake. Should Pfizer investors be worried about Moderna's lawsuits?Moderna's complaintModerna filed several patents between 2010 and 2016 related to its messenger RNA (mRNA) technology. This technology was foundational for the company's development of COVID-19 vaccine Spikevax. Moderna's mRNA vaccine won U.S. Emergency Use Authorization in December 2020 and secured full Food and Drug Administration (FDA) approval in January 2022.The crux of Moderna's lawsuits is an allegation that Pfizer and BioNTech's COVID-19 vaccine Comirnaty infringes on those patents. Moderna Chief Legal Officer Shannon Thyme Klinger stated in the company's press release last week: \"We believe that Pfizer and BioNTech unlawfully copied Moderna's inventions, and they have continued to use them without permission.\"Moderna maintains that Pfizer and BioNTech advanced four COVID-19 vaccine candidates into clinical testing but ultimately picked one with the exact same mRNA chemical modification as Spikevax. It also alleges that Pfizer and BioNTech copied an approach developed by Moderna for encoding the full-length spike protein found on the surface of the novel coronavirus in a lipid nanoparticle formulation.In October 2020, Moderna pledged that it wouldn't seek to enforce its COVID-19 patents during the pandemic. However, the company updated that pledge in March 2022 with COVID-19 vaccines readily available throughout much of the world. Moderna's revised commitment was to never enforce its patents for COVID-19 vaccines used in low- and middle-income countries. But the company didn't extend that promise to major developed markets.Potential impactWhat's the potential impact on Pfizer? Most importantly, Moderna isn't trying to remove Comirnaty from the market. Nor is it trying to prevent any future sales of the vaccine. Neither is Moderna seeking damages related to Pfizer's sales in any of the 92 countries covered in the GAVI COVAX Advance Market Commitment (known as AMC 92 countries).Pfizer and BioNTech could, though, be liable for patent infringement (if proven) related to any sales of Comirnaty outside of the AMC 92 countries from March 8, 2022 and afterward. This date is based on when Moderna updated its pledge related to enforcement of its COVID-19 patents.In the second quarter of 2022, Pfizer recorded $8.8 billion in sales of Comirnaty. Based on the big drugmaker's guidance, another $10 billion will be made in the second half of this year. We don't know exactly how much of Comirnaty's sales were from March 8 through the end of Q1, but it's likely at least in the ballpark of $3.4 billion. Adding all of this up, Pfizer will probably record more than $22 billion in sales of Comirnaty this year to which Moderna is seeking damages.Moderna didn't indicate the licensing terms that it thinks are acceptable. Should Moderna win in court, a 20% royalty (which isn't unusual) would require Pfizer and BioNTech to pay around $4.4 billion to Moderna plus any punitive damages assessed along with royalties on future sales of Comirnaty. Of course, Pfizer and BioNTech would share the financial burden.No worries?It's pretty clear that Pfizer investors aren't all that worried about the Moderna lawsuits. The big drugmaker's share price is down only slightly since the litigation was announced. As for BioNTech, the vaccine stock is actually up a little.Pfizer said in a written statement to CNN that it hasn't fully reviewed Moderna's complaint but was \"surprised by the litigation\" and would \"vigorously defend against the allegations of the lawsuit.\" Similarly, BioNTech said in a public statement that its \"work is original, and will vigorously defend against all allegations of patent infringement.\" BioNTech noted that these kinds of patent lawsuits are \"an unfortunate but rather regular occurrence.\"The courts will have to determine which side is right. However, Pfizer is making so much money from Comirnaty that it shouldn't feel too much pain even if Moderna wins.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9930684817,"gmtCreate":1661951626642,"gmtModify":1676536610273,"author":{"id":"3576055655100541","authorId":"3576055655100541","name":"BhaskarB","avatar":"https://static.tigerbbs.com/ae63d5d863287dbf3e7d25ef9ab845e0","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3576055655100541","idStr":"3576055655100541"},"htmlText":"Nope","listText":"Nope","text":"Nope","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9930684817","repostId":2263747723,"repostType":4,"repost":{"id":"2263747723","pubTimestamp":1661946110,"share":"https://ttm.financial/m/news/2263747723?lang=&edition=fundamental","pubTime":"2022-08-31 19:41","market":"us","language":"en","title":"Should Pfizer Investors Be Worried About Moderna's Lawsuits?","url":"https://stock-news.laohu8.com/highlight/detail?id=2263747723","media":"Motley Fool","summary":"Pfizer and BioNTech plan to aggressively defend against Moderna's claims of patent infringement.","content":"<html><head></head><body><p>A once-friendly rivalry isn&#39;t so friendly anymore. <a href=\"https://laohu8.com/S/MRNA\">Moderna </a> announced last Friday that it filed patent-infringement lawsuits against <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech </a> in the U.S. and Germany.</p><p>A portion of the billions of dollars made by Pfizer and BioNTech on sales of COVID-19 vaccine Comirnaty are at stake. Should Pfizer investors be worried about Moderna&#39;s lawsuits?</p><h2>Moderna&#39;s complaint</h2><p>Moderna filed several patents between 2010 and 2016 related to its messenger RNA (mRNA) technology. This technology was foundational for the company&#39;s development of COVID-19 vaccine Spikevax. Moderna&#39;s mRNA vaccine won U.S. Emergency Use Authorization in December 2020 and secured full Food and Drug Administration (FDA) approval in January 2022.</p><p>The crux of Moderna&#39;s lawsuits is an allegation that Pfizer and BioNTech&#39;s COVID-19 vaccine Comirnaty infringes on those patents. Moderna Chief Legal Officer Shannon Thyme Klinger stated in the company&#39;s press release last week: &#34;We believe that Pfizer and BioNTech unlawfully copied Moderna&#39;s inventions, and they have continued to use them without permission.&#34;</p><p>Moderna maintains that Pfizer and BioNTech advanced four COVID-19 vaccine candidates into clinical testing but ultimately picked one with the exact same mRNA chemical modification as Spikevax. It also alleges that Pfizer and BioNTech copied an approach developed by Moderna for encoding the full-length spike protein found on the surface of the novel coronavirus in a lipid nanoparticle formulation.</p><p>In October 2020, Moderna pledged that it wouldn&#39;t seek to enforce its COVID-19 patents during the pandemic. However, the company updated that pledge in March 2022 with COVID-19 vaccines readily available throughout much of the world. Moderna&#39;s revised commitment was to never enforce its patents for COVID-19 vaccines used in low- and middle-income countries. But the company didn&#39;t extend that promise to major developed markets.</p><h2>Potential impact</h2><p>What&#39;s the potential impact on Pfizer? Most importantly, Moderna isn&#39;t trying to remove Comirnaty from the market. Nor is it trying to prevent any future sales of the vaccine. Neither is Moderna seeking damages related to Pfizer&#39;s sales in any of the 92 countries covered in the GAVI COVAX Advance Market Commitment (known as AMC 92 countries).</p><p>Pfizer and BioNTech could, though, be liable for patent infringement (if proven) related to any sales of Comirnaty outside of the AMC 92 countries from March 8, 2022 and afterward. This date is based on when Moderna updated its pledge related to enforcement of its COVID-19 patents.</p><p>In the second quarter of 2022, Pfizer recorded $8.8 billion in sales of Comirnaty. Based on the big drugmaker&#39;s guidance, another $10 billion will be made in the second half of this year. We don&#39;t know exactly how much of Comirnaty&#39;s sales were from March 8 through the end of Q1, but it&#39;s likely at least in the ballpark of $3.4 billion. Adding all of this up, Pfizer will probably record more than $22 billion in sales of Comirnaty this year to which Moderna is seeking damages.</p><p>Moderna didn&#39;t indicate the licensing terms that it thinks are acceptable. Should Moderna win in court, a 20% royalty (which isn&#39;t unusual) would require Pfizer and BioNTech to pay around $4.4 billion to Moderna plus any punitive damages assessed along with royalties on future sales of Comirnaty. Of course, Pfizer and BioNTech would share the financial burden.</p><h2>No worries?</h2><p>It&#39;s pretty clear that Pfizer investors aren&#39;t all that worried about the Moderna lawsuits. The big drugmaker&#39;s share price is down only slightly since the litigation was announced. As for BioNTech, the vaccine stock is actually up a little.</p><p>Pfizer said in a written statement to CNN that it hasn&#39;t fully reviewed Moderna&#39;s complaint but was &#34;surprised by the litigation&#34; and would &#34;vigorously defend against the allegations of the lawsuit.&#34; Similarly, BioNTech said in a public statement that its &#34;work is original, and will vigorously defend against all allegations of patent infringement.&#34; BioNTech noted that these kinds of patent lawsuits are &#34;an unfortunate but rather regular occurrence.&#34;</p><p>The courts will have to determine which side is right. However, Pfizer is making so much money from Comirnaty that it shouldn&#39;t feel too much pain even if Moderna wins.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should Pfizer Investors Be Worried About Moderna's Lawsuits?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould Pfizer Investors Be Worried About Moderna's Lawsuits?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-08-31 19:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/08/31/should-pfizer-investors-be-worried-about-modernas/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A once-friendly rivalry isn't so friendly anymore. Moderna  announced last Friday that it filed patent-infringement lawsuits against Pfizer and BioNTech  in the U.S. and Germany.A portion of the ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/08/31/should-pfizer-investors-be-worried-about-modernas/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2022/08/31/should-pfizer-investors-be-worried-about-modernas/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2263747723","content_text":"A once-friendly rivalry isn't so friendly anymore. Moderna  announced last Friday that it filed patent-infringement lawsuits against Pfizer and BioNTech  in the U.S. and Germany.A portion of the billions of dollars made by Pfizer and BioNTech on sales of COVID-19 vaccine Comirnaty are at stake. Should Pfizer investors be worried about Moderna's lawsuits?Moderna's complaintModerna filed several patents between 2010 and 2016 related to its messenger RNA (mRNA) technology. This technology was foundational for the company's development of COVID-19 vaccine Spikevax. Moderna's mRNA vaccine won U.S. Emergency Use Authorization in December 2020 and secured full Food and Drug Administration (FDA) approval in January 2022.The crux of Moderna's lawsuits is an allegation that Pfizer and BioNTech's COVID-19 vaccine Comirnaty infringes on those patents. Moderna Chief Legal Officer Shannon Thyme Klinger stated in the company's press release last week: \"We believe that Pfizer and BioNTech unlawfully copied Moderna's inventions, and they have continued to use them without permission.\"Moderna maintains that Pfizer and BioNTech advanced four COVID-19 vaccine candidates into clinical testing but ultimately picked one with the exact same mRNA chemical modification as Spikevax. It also alleges that Pfizer and BioNTech copied an approach developed by Moderna for encoding the full-length spike protein found on the surface of the novel coronavirus in a lipid nanoparticle formulation.In October 2020, Moderna pledged that it wouldn't seek to enforce its COVID-19 patents during the pandemic. However, the company updated that pledge in March 2022 with COVID-19 vaccines readily available throughout much of the world. Moderna's revised commitment was to never enforce its patents for COVID-19 vaccines used in low- and middle-income countries. But the company didn't extend that promise to major developed markets.Potential impactWhat's the potential impact on Pfizer? Most importantly, Moderna isn't trying to remove Comirnaty from the market. Nor is it trying to prevent any future sales of the vaccine. Neither is Moderna seeking damages related to Pfizer's sales in any of the 92 countries covered in the GAVI COVAX Advance Market Commitment (known as AMC 92 countries).Pfizer and BioNTech could, though, be liable for patent infringement (if proven) related to any sales of Comirnaty outside of the AMC 92 countries from March 8, 2022 and afterward. This date is based on when Moderna updated its pledge related to enforcement of its COVID-19 patents.In the second quarter of 2022, Pfizer recorded $8.8 billion in sales of Comirnaty. Based on the big drugmaker's guidance, another $10 billion will be made in the second half of this year. We don't know exactly how much of Comirnaty's sales were from March 8 through the end of Q1, but it's likely at least in the ballpark of $3.4 billion. Adding all of this up, Pfizer will probably record more than $22 billion in sales of Comirnaty this year to which Moderna is seeking damages.Moderna didn't indicate the licensing terms that it thinks are acceptable. Should Moderna win in court, a 20% royalty (which isn't unusual) would require Pfizer and BioNTech to pay around $4.4 billion to Moderna plus any punitive damages assessed along with royalties on future sales of Comirnaty. Of course, Pfizer and BioNTech would share the financial burden.No worries?It's pretty clear that Pfizer investors aren't all that worried about the Moderna lawsuits. The big drugmaker's share price is down only slightly since the litigation was announced. As for BioNTech, the vaccine stock is actually up a little.Pfizer said in a written statement to CNN that it hasn't fully reviewed Moderna's complaint but was \"surprised by the litigation\" and would \"vigorously defend against the allegations of the lawsuit.\" Similarly, BioNTech said in a public statement that its \"work is original, and will vigorously defend against all allegations of patent infringement.\" BioNTech noted that these kinds of patent lawsuits are \"an unfortunate but rather regular occurrence.\"The courts will have to determine which side is right. However, Pfizer is making so much money from Comirnaty that it shouldn't feel too much pain even if Moderna wins.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9930634509,"gmtCreate":1661947725402,"gmtModify":1676536609549,"author":{"id":"3585038405943602","authorId":"3585038405943602","name":"Ahleepapa","avatar":"https://static.tigerbbs.com/dcc1fea9c38112b58c68a2d96017330b","vip":1,"crmLevel":1,"crmLevelSwitch":1,"authorIdStr":"3585038405943602","idStr":"3585038405943602"},"htmlText":"short","listText":"short","text":"short","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9930634509","repostId":2263747723,"repostType":4,"repost":{"id":"2263747723","pubTimestamp":1661946110,"share":"https://ttm.financial/m/news/2263747723?lang=&edition=fundamental","pubTime":"2022-08-31 19:41","market":"us","language":"en","title":"Should Pfizer Investors Be Worried About Moderna's Lawsuits?","url":"https://stock-news.laohu8.com/highlight/detail?id=2263747723","media":"Motley Fool","summary":"Pfizer and BioNTech plan to aggressively defend against Moderna's claims of patent infringement.","content":"<html><head></head><body><p>A once-friendly rivalry isn&#39;t so friendly anymore. <a href=\"https://laohu8.com/S/MRNA\">Moderna </a> announced last Friday that it filed patent-infringement lawsuits against <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech </a> in the U.S. and Germany.</p><p>A portion of the billions of dollars made by Pfizer and BioNTech on sales of COVID-19 vaccine Comirnaty are at stake. Should Pfizer investors be worried about Moderna&#39;s lawsuits?</p><h2>Moderna&#39;s complaint</h2><p>Moderna filed several patents between 2010 and 2016 related to its messenger RNA (mRNA) technology. This technology was foundational for the company&#39;s development of COVID-19 vaccine Spikevax. Moderna&#39;s mRNA vaccine won U.S. Emergency Use Authorization in December 2020 and secured full Food and Drug Administration (FDA) approval in January 2022.</p><p>The crux of Moderna&#39;s lawsuits is an allegation that Pfizer and BioNTech&#39;s COVID-19 vaccine Comirnaty infringes on those patents. Moderna Chief Legal Officer Shannon Thyme Klinger stated in the company&#39;s press release last week: &#34;We believe that Pfizer and BioNTech unlawfully copied Moderna&#39;s inventions, and they have continued to use them without permission.&#34;</p><p>Moderna maintains that Pfizer and BioNTech advanced four COVID-19 vaccine candidates into clinical testing but ultimately picked one with the exact same mRNA chemical modification as Spikevax. It also alleges that Pfizer and BioNTech copied an approach developed by Moderna for encoding the full-length spike protein found on the surface of the novel coronavirus in a lipid nanoparticle formulation.</p><p>In October 2020, Moderna pledged that it wouldn&#39;t seek to enforce its COVID-19 patents during the pandemic. However, the company updated that pledge in March 2022 with COVID-19 vaccines readily available throughout much of the world. Moderna&#39;s revised commitment was to never enforce its patents for COVID-19 vaccines used in low- and middle-income countries. But the company didn&#39;t extend that promise to major developed markets.</p><h2>Potential impact</h2><p>What&#39;s the potential impact on Pfizer? Most importantly, Moderna isn&#39;t trying to remove Comirnaty from the market. Nor is it trying to prevent any future sales of the vaccine. Neither is Moderna seeking damages related to Pfizer&#39;s sales in any of the 92 countries covered in the GAVI COVAX Advance Market Commitment (known as AMC 92 countries).</p><p>Pfizer and BioNTech could, though, be liable for patent infringement (if proven) related to any sales of Comirnaty outside of the AMC 92 countries from March 8, 2022 and afterward. This date is based on when Moderna updated its pledge related to enforcement of its COVID-19 patents.</p><p>In the second quarter of 2022, Pfizer recorded $8.8 billion in sales of Comirnaty. Based on the big drugmaker&#39;s guidance, another $10 billion will be made in the second half of this year. We don&#39;t know exactly how much of Comirnaty&#39;s sales were from March 8 through the end of Q1, but it&#39;s likely at least in the ballpark of $3.4 billion. Adding all of this up, Pfizer will probably record more than $22 billion in sales of Comirnaty this year to which Moderna is seeking damages.</p><p>Moderna didn&#39;t indicate the licensing terms that it thinks are acceptable. Should Moderna win in court, a 20% royalty (which isn&#39;t unusual) would require Pfizer and BioNTech to pay around $4.4 billion to Moderna plus any punitive damages assessed along with royalties on future sales of Comirnaty. Of course, Pfizer and BioNTech would share the financial burden.</p><h2>No worries?</h2><p>It&#39;s pretty clear that Pfizer investors aren&#39;t all that worried about the Moderna lawsuits. The big drugmaker&#39;s share price is down only slightly since the litigation was announced. As for BioNTech, the vaccine stock is actually up a little.</p><p>Pfizer said in a written statement to CNN that it hasn&#39;t fully reviewed Moderna&#39;s complaint but was &#34;surprised by the litigation&#34; and would &#34;vigorously defend against the allegations of the lawsuit.&#34; Similarly, BioNTech said in a public statement that its &#34;work is original, and will vigorously defend against all allegations of patent infringement.&#34; BioNTech noted that these kinds of patent lawsuits are &#34;an unfortunate but rather regular occurrence.&#34;</p><p>The courts will have to determine which side is right. However, Pfizer is making so much money from Comirnaty that it shouldn&#39;t feel too much pain even if Moderna wins.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should Pfizer Investors Be Worried About Moderna's Lawsuits?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould Pfizer Investors Be Worried About Moderna's Lawsuits?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-08-31 19:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/08/31/should-pfizer-investors-be-worried-about-modernas/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A once-friendly rivalry isn't so friendly anymore. Moderna  announced last Friday that it filed patent-infringement lawsuits against Pfizer and BioNTech  in the U.S. and Germany.A portion of the ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/08/31/should-pfizer-investors-be-worried-about-modernas/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2022/08/31/should-pfizer-investors-be-worried-about-modernas/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2263747723","content_text":"A once-friendly rivalry isn't so friendly anymore. Moderna  announced last Friday that it filed patent-infringement lawsuits against Pfizer and BioNTech  in the U.S. and Germany.A portion of the billions of dollars made by Pfizer and BioNTech on sales of COVID-19 vaccine Comirnaty are at stake. Should Pfizer investors be worried about Moderna's lawsuits?Moderna's complaintModerna filed several patents between 2010 and 2016 related to its messenger RNA (mRNA) technology. This technology was foundational for the company's development of COVID-19 vaccine Spikevax. Moderna's mRNA vaccine won U.S. Emergency Use Authorization in December 2020 and secured full Food and Drug Administration (FDA) approval in January 2022.The crux of Moderna's lawsuits is an allegation that Pfizer and BioNTech's COVID-19 vaccine Comirnaty infringes on those patents. Moderna Chief Legal Officer Shannon Thyme Klinger stated in the company's press release last week: \"We believe that Pfizer and BioNTech unlawfully copied Moderna's inventions, and they have continued to use them without permission.\"Moderna maintains that Pfizer and BioNTech advanced four COVID-19 vaccine candidates into clinical testing but ultimately picked one with the exact same mRNA chemical modification as Spikevax. It also alleges that Pfizer and BioNTech copied an approach developed by Moderna for encoding the full-length spike protein found on the surface of the novel coronavirus in a lipid nanoparticle formulation.In October 2020, Moderna pledged that it wouldn't seek to enforce its COVID-19 patents during the pandemic. However, the company updated that pledge in March 2022 with COVID-19 vaccines readily available throughout much of the world. Moderna's revised commitment was to never enforce its patents for COVID-19 vaccines used in low- and middle-income countries. But the company didn't extend that promise to major developed markets.Potential impactWhat's the potential impact on Pfizer? Most importantly, Moderna isn't trying to remove Comirnaty from the market. Nor is it trying to prevent any future sales of the vaccine. Neither is Moderna seeking damages related to Pfizer's sales in any of the 92 countries covered in the GAVI COVAX Advance Market Commitment (known as AMC 92 countries).Pfizer and BioNTech could, though, be liable for patent infringement (if proven) related to any sales of Comirnaty outside of the AMC 92 countries from March 8, 2022 and afterward. This date is based on when Moderna updated its pledge related to enforcement of its COVID-19 patents.In the second quarter of 2022, Pfizer recorded $8.8 billion in sales of Comirnaty. Based on the big drugmaker's guidance, another $10 billion will be made in the second half of this year. We don't know exactly how much of Comirnaty's sales were from March 8 through the end of Q1, but it's likely at least in the ballpark of $3.4 billion. Adding all of this up, Pfizer will probably record more than $22 billion in sales of Comirnaty this year to which Moderna is seeking damages.Moderna didn't indicate the licensing terms that it thinks are acceptable. Should Moderna win in court, a 20% royalty (which isn't unusual) would require Pfizer and BioNTech to pay around $4.4 billion to Moderna plus any punitive damages assessed along with royalties on future sales of Comirnaty. Of course, Pfizer and BioNTech would share the financial burden.No worries?It's pretty clear that Pfizer investors aren't all that worried about the Moderna lawsuits. The big drugmaker's share price is down only slightly since the litigation was announced. As for BioNTech, the vaccine stock is actually up a little.Pfizer said in a written statement to CNN that it hasn't fully reviewed Moderna's complaint but was \"surprised by the litigation\" and would \"vigorously defend against the allegations of the lawsuit.\" Similarly, BioNTech said in a public statement that its \"work is original, and will vigorously defend against all allegations of patent infringement.\" BioNTech noted that these kinds of patent lawsuits are \"an unfortunate but rather regular occurrence.\"The courts will have to determine which side is right. However, Pfizer is making so much money from Comirnaty that it shouldn't feel too much pain even if Moderna wins.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9930639791,"gmtCreate":1661946333415,"gmtModify":1676536609319,"author":{"id":"3574372061770129","authorId":"3574372061770129","name":"watever","avatar":"https://static.tigerbbs.com/7f621f8815426f0f78f2e35ecc0414e8","vip":1,"crmLevel":2,"crmLevelSwitch":1,"authorIdStr":"3574372061770129","idStr":"3574372061770129"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9930639791","repostId":2263747723,"repostType":4,"repost":{"id":"2263747723","pubTimestamp":1661946110,"share":"https://ttm.financial/m/news/2263747723?lang=&edition=fundamental","pubTime":"2022-08-31 19:41","market":"us","language":"en","title":"Should Pfizer Investors Be Worried About Moderna's Lawsuits?","url":"https://stock-news.laohu8.com/highlight/detail?id=2263747723","media":"Motley Fool","summary":"Pfizer and BioNTech plan to aggressively defend against Moderna's claims of patent infringement.","content":"<html><head></head><body><p>A once-friendly rivalry isn&#39;t so friendly anymore. <a href=\"https://laohu8.com/S/MRNA\">Moderna </a> announced last Friday that it filed patent-infringement lawsuits against <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech </a> in the U.S. and Germany.</p><p>A portion of the billions of dollars made by Pfizer and BioNTech on sales of COVID-19 vaccine Comirnaty are at stake. Should Pfizer investors be worried about Moderna&#39;s lawsuits?</p><h2>Moderna&#39;s complaint</h2><p>Moderna filed several patents between 2010 and 2016 related to its messenger RNA (mRNA) technology. This technology was foundational for the company&#39;s development of COVID-19 vaccine Spikevax. Moderna&#39;s mRNA vaccine won U.S. Emergency Use Authorization in December 2020 and secured full Food and Drug Administration (FDA) approval in January 2022.</p><p>The crux of Moderna&#39;s lawsuits is an allegation that Pfizer and BioNTech&#39;s COVID-19 vaccine Comirnaty infringes on those patents. Moderna Chief Legal Officer Shannon Thyme Klinger stated in the company&#39;s press release last week: &#34;We believe that Pfizer and BioNTech unlawfully copied Moderna&#39;s inventions, and they have continued to use them without permission.&#34;</p><p>Moderna maintains that Pfizer and BioNTech advanced four COVID-19 vaccine candidates into clinical testing but ultimately picked one with the exact same mRNA chemical modification as Spikevax. It also alleges that Pfizer and BioNTech copied an approach developed by Moderna for encoding the full-length spike protein found on the surface of the novel coronavirus in a lipid nanoparticle formulation.</p><p>In October 2020, Moderna pledged that it wouldn&#39;t seek to enforce its COVID-19 patents during the pandemic. However, the company updated that pledge in March 2022 with COVID-19 vaccines readily available throughout much of the world. Moderna&#39;s revised commitment was to never enforce its patents for COVID-19 vaccines used in low- and middle-income countries. But the company didn&#39;t extend that promise to major developed markets.</p><h2>Potential impact</h2><p>What&#39;s the potential impact on Pfizer? Most importantly, Moderna isn&#39;t trying to remove Comirnaty from the market. Nor is it trying to prevent any future sales of the vaccine. Neither is Moderna seeking damages related to Pfizer&#39;s sales in any of the 92 countries covered in the GAVI COVAX Advance Market Commitment (known as AMC 92 countries).</p><p>Pfizer and BioNTech could, though, be liable for patent infringement (if proven) related to any sales of Comirnaty outside of the AMC 92 countries from March 8, 2022 and afterward. This date is based on when Moderna updated its pledge related to enforcement of its COVID-19 patents.</p><p>In the second quarter of 2022, Pfizer recorded $8.8 billion in sales of Comirnaty. Based on the big drugmaker&#39;s guidance, another $10 billion will be made in the second half of this year. We don&#39;t know exactly how much of Comirnaty&#39;s sales were from March 8 through the end of Q1, but it&#39;s likely at least in the ballpark of $3.4 billion. Adding all of this up, Pfizer will probably record more than $22 billion in sales of Comirnaty this year to which Moderna is seeking damages.</p><p>Moderna didn&#39;t indicate the licensing terms that it thinks are acceptable. Should Moderna win in court, a 20% royalty (which isn&#39;t unusual) would require Pfizer and BioNTech to pay around $4.4 billion to Moderna plus any punitive damages assessed along with royalties on future sales of Comirnaty. Of course, Pfizer and BioNTech would share the financial burden.</p><h2>No worries?</h2><p>It&#39;s pretty clear that Pfizer investors aren&#39;t all that worried about the Moderna lawsuits. The big drugmaker&#39;s share price is down only slightly since the litigation was announced. As for BioNTech, the vaccine stock is actually up a little.</p><p>Pfizer said in a written statement to CNN that it hasn&#39;t fully reviewed Moderna&#39;s complaint but was &#34;surprised by the litigation&#34; and would &#34;vigorously defend against the allegations of the lawsuit.&#34; Similarly, BioNTech said in a public statement that its &#34;work is original, and will vigorously defend against all allegations of patent infringement.&#34; BioNTech noted that these kinds of patent lawsuits are &#34;an unfortunate but rather regular occurrence.&#34;</p><p>The courts will have to determine which side is right. However, Pfizer is making so much money from Comirnaty that it shouldn&#39;t feel too much pain even if Moderna wins.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should Pfizer Investors Be Worried About Moderna's Lawsuits?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould Pfizer Investors Be Worried About Moderna's Lawsuits?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-08-31 19:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/08/31/should-pfizer-investors-be-worried-about-modernas/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A once-friendly rivalry isn't so friendly anymore. Moderna  announced last Friday that it filed patent-infringement lawsuits against Pfizer and BioNTech  in the U.S. and Germany.A portion of the ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/08/31/should-pfizer-investors-be-worried-about-modernas/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2022/08/31/should-pfizer-investors-be-worried-about-modernas/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2263747723","content_text":"A once-friendly rivalry isn't so friendly anymore. Moderna  announced last Friday that it filed patent-infringement lawsuits against Pfizer and BioNTech  in the U.S. and Germany.A portion of the billions of dollars made by Pfizer and BioNTech on sales of COVID-19 vaccine Comirnaty are at stake. Should Pfizer investors be worried about Moderna's lawsuits?Moderna's complaintModerna filed several patents between 2010 and 2016 related to its messenger RNA (mRNA) technology. This technology was foundational for the company's development of COVID-19 vaccine Spikevax. Moderna's mRNA vaccine won U.S. Emergency Use Authorization in December 2020 and secured full Food and Drug Administration (FDA) approval in January 2022.The crux of Moderna's lawsuits is an allegation that Pfizer and BioNTech's COVID-19 vaccine Comirnaty infringes on those patents. Moderna Chief Legal Officer Shannon Thyme Klinger stated in the company's press release last week: \"We believe that Pfizer and BioNTech unlawfully copied Moderna's inventions, and they have continued to use them without permission.\"Moderna maintains that Pfizer and BioNTech advanced four COVID-19 vaccine candidates into clinical testing but ultimately picked one with the exact same mRNA chemical modification as Spikevax. It also alleges that Pfizer and BioNTech copied an approach developed by Moderna for encoding the full-length spike protein found on the surface of the novel coronavirus in a lipid nanoparticle formulation.In October 2020, Moderna pledged that it wouldn't seek to enforce its COVID-19 patents during the pandemic. However, the company updated that pledge in March 2022 with COVID-19 vaccines readily available throughout much of the world. Moderna's revised commitment was to never enforce its patents for COVID-19 vaccines used in low- and middle-income countries. But the company didn't extend that promise to major developed markets.Potential impactWhat's the potential impact on Pfizer? Most importantly, Moderna isn't trying to remove Comirnaty from the market. Nor is it trying to prevent any future sales of the vaccine. Neither is Moderna seeking damages related to Pfizer's sales in any of the 92 countries covered in the GAVI COVAX Advance Market Commitment (known as AMC 92 countries).Pfizer and BioNTech could, though, be liable for patent infringement (if proven) related to any sales of Comirnaty outside of the AMC 92 countries from March 8, 2022 and afterward. This date is based on when Moderna updated its pledge related to enforcement of its COVID-19 patents.In the second quarter of 2022, Pfizer recorded $8.8 billion in sales of Comirnaty. Based on the big drugmaker's guidance, another $10 billion will be made in the second half of this year. We don't know exactly how much of Comirnaty's sales were from March 8 through the end of Q1, but it's likely at least in the ballpark of $3.4 billion. Adding all of this up, Pfizer will probably record more than $22 billion in sales of Comirnaty this year to which Moderna is seeking damages.Moderna didn't indicate the licensing terms that it thinks are acceptable. Should Moderna win in court, a 20% royalty (which isn't unusual) would require Pfizer and BioNTech to pay around $4.4 billion to Moderna plus any punitive damages assessed along with royalties on future sales of Comirnaty. Of course, Pfizer and BioNTech would share the financial burden.No worries?It's pretty clear that Pfizer investors aren't all that worried about the Moderna lawsuits. The big drugmaker's share price is down only slightly since the litigation was announced. As for BioNTech, the vaccine stock is actually up a little.Pfizer said in a written statement to CNN that it hasn't fully reviewed Moderna's complaint but was \"surprised by the litigation\" and would \"vigorously defend against the allegations of the lawsuit.\" Similarly, BioNTech said in a public statement that its \"work is original, and will vigorously defend against all allegations of patent infringement.\" BioNTech noted that these kinds of patent lawsuits are \"an unfortunate but rather regular occurrence.\"The courts will have to determine which side is right. However, Pfizer is making so much money from Comirnaty that it shouldn't feel too much pain even if Moderna wins.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":34,"commentSize":7,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}